Mid-Atlantic BioTherapeutics, Inc. (MABT)
Engineering the next wave in immunotherapy
MABT is a clinical-stage company focused on HIV/AIDS. Our lead compound, IMT504, has shown impressive results in animal safety and efficacy models and in humans, including some exciting new primate data suggesting that IMT504 could help lead to a functional cure for HIV/AIDS. MABT anticipates initiating human testing to show the therapeutic benefit of IMT504 in HIV/AIDS patients.